ClinicalTrials.gg
DrugBiological

Complement C1 Inhibitor Protein clinical trials

Also written C1 Esterase Inhibitor.

studies test it
26
open now
1
in phase 3
13
first study started
2004

Counted the way a researcher would: Complement C1 Inhibitor Protein with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Complement C1 Inhibitor Protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Complement C1 Inhibitor Protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Jul 2014 · Ruconest · BLA 125495 (FDA, Purple Book)
European Union
28 Oct 2010 · Ruconest · EMEA/H/C/001223 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

C1-esterase inhibitor
6
C1 esterase inhibitor [human] (C1INH-nf)
5
C1-inhibitor
3
Berinert P
3
Cinryze
3

Development codes

CE1145
1

Other names

C1 Esterase Inhibitor
4

In one entry with another drug

Given together, or one or the other

Recombinant Human C1 Inhibitor
4
"rhC1INH"
3

Studies by the year they started

26 studies that test it; most in 2005 (5)

Studies that test Complement C1 Inhibitor Protein, by start year
YearStudies
20041
20055
20063
20082
20091
20111
20122
20132
20144
20162
20171
20181
20241

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
4
Phase 2
9
Phase 3
13
Phase 4
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 11

Shire (5) · CSL Behring (4) · Pharming Technologies B.V. (4) · Radboud University Medical Center (2) · Universitaire Ziekenhuizen KU Leuven (1) · IMMUNOe Research Centers (1) · NYU Langone Health (1) · Cedars-Sinai Medical Center (1)

Often tested with

Tested in the same studies.

Conestat alfa (4) · C1 esterase inhibitor (human) (4) · Antithrombin-III (1) · Antithrombin III (1) · Infliximab (1) · Apotransferrin (1) · Glutathione (1) · Melatonin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Complement C1 Inhibitor Protein.

Studies

Open first, then newest update. How each study uses Complement C1 Inhibitor Protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 26

See all 26 studies that test Complement C1 Inhibitor Protein →

Codes

What other systems call Complement C1 Inhibitor Protein · ClinicalTrials.gg INT008866

  • MeSH (NLM) D050718Complement C1 Inhibitor ProteinOne source ClinicalTrials.gov
  • RxNorm 1599831One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.